Fig. 2From: Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancerROC curve analysis to determinate the power of discrimination of the biomarkers between different patient response. Univariate approach for (A) CTC counts (AUC = 0.585; sensitivity = 47.6%; specificity = 63.3%), B cfDNA yield (AUC = 0.593; sensitivity = 59.8%; specificity = 46.7%), C CA15-3 levels (AUC = 0.491; sensitivity = 54.9%; specificity = 46.7%) and D AP levels (AUC = 0.573, sensitivity = 68.3%, specificity = 46.7%)Back to article page